Analyst Price Targets — BAX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 17, 2026 3:01 pm | — | Goldman Sachs | $17.00 | $20.54 | TheFly | Baxter price target lowered to $17 from $21 at Goldman Sachs |
| February 16, 2026 12:51 pm | Danielle Antalffy | UBS | $19.00 | $19.79 | TheFly | Baxter price target lowered to $19 from $21 at UBS |
| February 13, 2026 1:36 pm | — | Deutsche Bank | $20.00 | $19.23 | TheFly | Baxter price target lowered to $20 from $22 at Deutsche Bank |
| February 13, 2026 11:08 am | — | Barclays | $25.00 | $18.71 | TheFly | Baxter price target lowered to $25 from $30 at Barclays |
| February 12, 2026 8:55 pm | — | Jefferies | $19.00 | $18.71 | TheFly | Baxter price target lowered to $19 from $21 at Jefferies |
| February 12, 2026 8:43 pm | — | Stifel Nicolaus | $20.00 | $18.71 | TheFly | Baxter price target lowered to $20 from $22 at Stifel |
| January 9, 2026 12:19 pm | Matt Miksic | Barclays | $30.00 | $20.69 | TheFly | Baxter price target lowered to $30 from $36 at Barclays |
| January 9, 2026 10:46 am | — | Goldman Sachs | $23.00 | $20.69 | TheFly | Baxter price target raised to $23 from $22 at Goldman Sachs |
| January 5, 2026 2:46 pm | Vijay Kumar | Evercore ISI | $23.00 | $20.03 | TheFly | Baxter price target lowered to $23 from $24 at Evercore ISI |
| December 2, 2025 11:39 am | Patrick Wood | Morgan Stanley | $15.00 | $19.08 | TheFly | Baxter price target lowered to $15 from $19 at Morgan Stanley |
Latest News for BAX
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, is highlighting recent additions to its Global Surgical Solutions and Patient Support Systems portfolios, as well as its broad Advanced Surgery portfolio of hemostatic and sealing agents, at the Association of periOperative Registered Nurses (AORN) Global Surgical Conference & Expo, taking place April 11-14, 2026 in New…
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its first-quarter 2026 financial results on Thursday, April 30, 2026 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I946023356 to pre-register for the call and receive the call information.…
Shares of Baxter International Inc. (NYSE: BAX - Get Free Report) have been assigned a consensus rating of "Hold" from the thirteen analysts that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have assigned a buy rating to
Baxter International (NYSE: BAX - Get Free Report) and Zynex (NASDAQ: ZYXI - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends. Insider and Institutional Ownership 90.2% of Baxter International shares
BAX introduces the IV Verify system to improve IV labeling accuracy, targeting medication safety gaps and boosting workflow efficiency in clinical settings.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.